Blagden, Sarah P.
Rizzuto, Ivana
Suppiah, Puvan
O’Shea, Daniel
Patel, Markand
Spiers, Laura
Sukumaran, Ajithkumar
Bharwani, Nishat
Rockall, Andrea
Gabra, Hani
El-Bahrawy, Mona
Wasan, Harpreet
Leonard, Robert
Habib, Nagy
Ghazaly, Essam
Funding for this research was provided by:
Nucana PLC
Article History
Received: 14 March 2018
Revised: 19 July 2018
Accepted: 2 August 2018
First Online: 12 September 2018
Competing interests
: For the duration of this study, E.G. was employed by Queen Mary’s University, London, and received research funding from NuCana plc to conduct the pharmacokinetic assessments described in this manuscript. Following this study, I.R. received research funding from NuCana plc. The other authors declare no competing interests.
: This manuscript does not contains any individual patient’s data or identifiable information
: Prior to participation in the study, all patients signed an informed consent document approved by the West London Research Ethics Committee (reference 12/LO/1100). The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.
: The study was sponsored by Imperial College London and funded by NuCana plc.
: The datasets used and analysed during the current study are available from the corresponding author on reasonable request.